Analyzing tumor samples from the CAPRI-GOIM trial, Normanno et al found that KRAS and NRAS mutations were present in a majority of tumor cells, but PIK3CA and BRAF mutations were only in a fraction of tumor cells [30], suggesting that biopsies from the site of the planned treatment should be performed optimally when feasible. The gene discussed is KRAS; the disease is neoplasm.